Objective    To study the effect of puerarin treatment on expression of platelet activation biomarkers

glycoprotein Ⅵ(GPⅥ) and CD62P

in patients with ischemic cerebral stroke.     Methods    Expression of GPⅥ and CD62P was detected by flow cytometry（FCM） before and after puerarin treatment in 50 ischemic cerebral stroke patients from Jan. to Jun. 2009 in Foshan Third People’s Hospital. Another 50 health individuals served as normal control. Soluble GPⅥ(sGPⅥ) in plasma of patients with ischemic cerebral stroke was assayed with double antibody sandwich ELISA. Correlation between expressions of platelet GPⅥ and CD62P

and between expressions of platelet and sGPⅥ was observed by linear correlation analysis.     Results    The expression level of platelet GPⅥ and CD62P was significantly higher in patients with ischemic cerebral stroke than in normal control group (P0.01）and was significantly lower after than before treatment with puerarin（P0.05）

but still higher than in normal control group （P0.05）. A significant positive linear correlation was observed between expressions of platelet GPⅥ and CD62P （r=0.784

P0.01）. The sGPⅥ level was significantly lower in patients with ischemic cerebral stroke than in normal control group（P0.01）. A significant negative linear correlation was found between expressions of platelet GPⅥ and sGPⅥ (r=-0.828，P0.01).          Conclusion    Both GPⅥ and CD62P can be used as biomarkers of platelet activation in patients with ischemic cerebral stroke with a similar sensitivity. Detection of GPⅥ and CD62P helps rational use of drugs in clinical practice. Plasma sGPⅥ can also be used as a parameter for the assessment of activated platelets.